COLORECTAL CANCER BY THE NUMBERSCOLORECTAL CANCER, OR CRC, IS THE 3RD MOST COMMONLY DIAGNOSED CANCER IN THE WORLD.

WORLDWIDE INCIDENCE IS EXPECTED TO INCREASE FROM 1.8 MILLION CASES DIAGNOSED IN 2018 TO 3.1 MILLION CASES BY 2040.

1,026,000

823,300

CRC MORE COMMON

IN MEN THAN WOMEN

MEDIAN AGE

67

73

AT DIAGNOSIS

AT DEATH

Source: American Cancer Society 2018

STAGING & SURVIVAL RATES

5-YearRelativeSurvivalRates

THERE ARE FOUR STAGES OF CRC. PATIENTS WITH

ADVANCED FORMS OF THE DISEASE HAVE FEWER

TREATMENT OPTIONS & LOWER SURVIVAL RATES.

RATES VARY GLOBALLY,

DEPENDING ON THE STAGE AND

TYPE OF COLORECTAL CANCER:

COLON CANCER RECTAL CANCER

92% 88%

81% 83%

13%

87% 90%

12%

STAGE I

STAGE I I

STAGE I I I

STAGE IV

STAGE I

STAGE I I

STAGE I I I

STAGE IV

53%

65%

50%

58%

LOW HIGH

COMMON RISK FACTORS

HEAVYALCOHOL USE

SMOKINGOBESITY

AGEOVER 50

FAMILYHISTORY

PHYSICALINACTIVITY

50+

WEAKNESS AND FATIGUE

UNINTENDED WEIGHT LOSS

CHANGE IN BOWEL HABITS(SUCH AS DIARRHEA& CONSTIPATION)

RECTAL BLEEDING

BLOOD IN THE STOOL

CRAMPING OR ABDOMINAL PAIN

SIGNS & SYMPTOMSTREATMENT OPTIONS

SURGERY RADIATIONTHERAPY

TARGETEDTHERAPY

© 2018 Bristol-Myers Squibb Company

ESTIMATED NUMBERS OF ANNUAL NEW CRC CASES BY REGION (THOUSANDS)

EUROPE499.6

CENTRAL AMERICA19.5

SOUTH AMERICA97.6

AFRICA61.8

AUSTRALIA & NEW ZEALAND21.2

COLORECTAL CANCER “HOT SPOTS”

NORTH AMERICA179.7

ASIA957.9

Source: Globocan 2018

CRC OFTEN BEGINS AS A GROWTH CALLED

A POLYP, WHICH MAY FORM ON THE INNER

WALL OF THE COLON OR RECTUM.

MICROSATELLITE INSTABILITY HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENT (dMMR) CRC

SOME CASES OF CRC ARE MSI-H OR dMMR, WHICH OCCURS WHEN THERE ARE

DEFICIENCIES IN THE CELL'S ABILITY TO REPAIR DNA ERRORS DURING CELL DIVISION.

5-YEAR SURVIVAL RATE RANGE:

APPROXIMATELY 15%

OF ALL PATIENTS

WITH CRC HAVE MSI-H

OR dMMR TUMORS.

ABOUT 4-5% OF PATIENTS

WITH METASTATIC CRC HAVE

MSI-H OR dMMR TUMORS.

PATIENTS WITH MSI-H OR dMMR METASTATIC CRC TYPICALLY HAVE A POOR PROGNOSIS WITH

LOWER SURVIVAL RATES COMPARED TO PATIENTS WHOSE TUMORS ARE NOT MSI-H OR dMMR.

A PATIENT’S TREATMENT OPTIONS

ARE LARGELY DEPENDENT ON STAGE

OF DISEASE, AND IN SOME CASES

BIOMARKERS, AND MAY INCLUDE:

CHEMOTHERAPY IMMUNOTHERAPY

WHAT IS CRC?

CRC IS A CANCER THAT FORMS IN THE TISSUES OF THE COLON OR RECTUM,

WHICH ARE PART OF THE BODY’S DIGESTIVE OR GASTROINTESTINAL (GI) SYSTEM.